Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moBUMETANIDE (bumetanide) by Aspiro Therapeutics is clinical pharmacology bumetanide tablets are loop diuretics with a rapid onset and short duration of action. Approved for edema associated with congestive heart failure, hepatic, renal disease and 2 more indications. First approved in 2025.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Bumetanide tablets are loop diuretics with a rapid onset and short duration of action. Pharmacological and clinical studies have shown that 1 mg bumetanide tablets have a diuretic potency equivalent to approximately 40 mg furosemide. The major site of bumetanide tablets action…
Worked on BUMETANIDE at Aspiro Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Loop Diuretic
Bumetanide vs. Furosemide in Cirrhosis
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
Pilot Study of Bumetanide for Newborn Seizures
Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo